Latest wrinkle in Allergan case
Allergan Inc., maker of the wrinkle smoother Botox, said it agreed to pay $600 million and plead guilty to a single misdemeanor charge in settling a U.S. investigation of its marketing practices.
Allergan will pay $375 million to the government as part of a “misbranding” charge that the marketing of Botox from 2000 to 2005 led to intended use in treating headache, pain, muscle stiffness and juvenile cerebral palsy, which were not approved by the Food and Drug Administration during that time.
Allergan will also pay $225 million to resolve civil claims from the Justice Department, the company said Wednesday in a statement.
Read more: http://www.kansascity.com/2010/09/01/2194022/consumer-memo-botox-settlement.html#ixzz0yLceJuM4
Labels: Health and Pharma